Physical activity among people with an inflammatory bowel disease: a systematic review of antecedents.

Psychol Health MedAug 6, 2025 (epub)
Clinical ResearchGastroenterology

Cameron Trim, Sharan Srinivasa Gopalan, Ryan Rhodes

✦ AI-curated · Sources linked

In 30 seconds

This systematic review synthesized research on factors associated with physical activity among people with inflammatory bowel disease (IBD), including differences between Crohn’s disease and ulcerative colitis. Searches identified 14 eligible papers involving 3,985 participants. Modified thematic analysis of quantitative and qualitative findings identified disease activity, fatigue, depression, pain and urgency as the most influential antecedents. These factors mapped to physical capability, reflective motivation and physical opportunity in the COM-B behaviour-change model. The review also found indications that people with Crohn’s disease face more barriers and undertake less total physical activity, but the authors cautioned that few studies support this comparison.

Key findings

  • Across 14 papers and 3,985 participants, disease activity, fatigue, depression, pain and urgency were the most influential antecedents of physical activity.
  • The identified antecedents affected physical capability, reflective motivation and physical opportunity in the COM-B model.
  • People with Crohn’s disease appeared to face more barriers and engage in less total physical activity than those with ulcerative colitis, but few studies informed this finding.

Why it matters

Understanding barriers to physical activity can help frame interventions around the challenges people with IBD report, rather than treating activity as a matter of motivation alone. The review highlights symptoms and disease activity alongside opportunity and capability, while its tentative subgroup comparison underscores the need for stronger evidence before assuming barriers are consistent across IBD diagnoses.

What to keep in mind

The Crohn’s disease–ulcerative colitis comparison was based on a small number of studies. The authors also noted a need for longitudinal and experimental research and more homogeneous samples to enable definitive quantitative synthesis.

Source

Published in Psychol Health Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.